The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster
Sponsored by Beijing Tiantan Hospital
About this trial
Last updated 3 months ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Started 4 months ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
* 1. Ages more than 18 years;
* 2. Patients with onset of HZ rash less than 90 days;
* 3. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
* 4. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
* 5. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher;
* 6. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.
Exclusion Criteria
* 1. History of applying flurbiprofen patch;
* 2. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;
* 3. History of intolerance or hypersensitivity to any active components or excipient of the flurbiprofen patch;
* 4. History of systemic immune diseases, organ transplantation, or cancers;
* 5. Pregnancy or breastfeeding.
